A randomized phase II trial comparing two doses of pulsed erlotinib prechemotherapy (PEP-C) in patients with stage IIIB or IV non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Feb 2009 Results published in Journal of Clinical Oncology 27: 264-270, No. 2, 10 Jan 2009
- 03 Feb 2009 Status changed from active, no longer recruiting to completed.
- 10 Jan 2009 Staus change from active, no longer recruiting to completed